Consequently, GPER constitutes a groundbreaking therapeutic target, with G-1 serving as a first-in-class therapeutic drug for the treatment of obesity and its related comorbidities, such as T2DM [281,296]. The gene discussed is GPER1; the disease is obesity disorder.